Novel 6-substituted uracil analogs as inhibitors of the angiogenic actions of thymidine phosphorylase

Biochemical Pharmacology

Volumn 62, Issue 9, 2001, Pages 1257-1263

  Klein, Robert S ^a   Lenzi, Michelle ^a   Lim, Timothy H ^a   Hotchkiss, Kylie A ^a   Wilson, Phyllis ^a   Schwartz, Edward L ^a  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

Angiogenesis; Endothelial cells; Thymidine phosphorylase

Indexed keywords

5 BROMO 6 AMINOURACIL; 5 CHLORO 6 (1 IMIDAZOLYLMETHYL)URACIL; 6 (2 AMINOETHYL)AMINO 5 CHLOROURACIL; ANGIOGENIC FACTOR; PURINE NUCLEOSIDE PHOSPHORYLASE; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; URACIL DERIVATIVE; URIDINE PHOSPHORYLASE; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; CELL MIGRATION; COCULTURE; COLON CARCINOMA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDINE PHOSPHORYLASE; TUMOR CELLS, CULTURED; URACIL;

EID: 0035504659     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(01)00783-3     Document Type: Article

References (48)

1. Angiogenesis
2. Expression of PD-ECGF factor in E. coli and confirmation of its thymidine phosphorylase activity
3. Angiogenic factor
4. Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor
5. Thymidine phosphorylase activity of platelet-derived endothelial cell growth factor is responsible for endothelial cell mitogenicity
6. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor
7. Thymidine phosphorylase is angiogenic and promotes tumor growth
8. The value of platelet-derived endothelial cell growth factor as a novel predictor of advancement of uterine cervical cancers
9. Purification and tissue distribution of human thymidine phosphorylase: High expression in lymphocytes, reticulocytes and tumors
10. Demonstration of thymidine phosphorylase activity in human healthy, adenomatous and cancerous prostate
11. A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa
12. Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor
13. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers
14. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis
15. Prognostic significance of angiogenesis in human pancreatic cancer
16. The activity and expression of thymidine phosphorylase in human solid tumors
17. Pyrimidine nucleotide metabolism in human colon carcinomas: Comparison of normal tissues, primary tumors and xenografts
18. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal cancer
19. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: Role of infiltrating cells
20. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with non-response to 5-fluorouracil
21. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal tumors
22. Inhibition of thymidine phosphorylase by 6-aminothymine and derivatives of 6-aminouracil
23. Irreversible enzyme inhibitors. 188. Inhibition of mammalian thymidine phosphorylase
24. Structure-activity relationship of ligands of the pyrimidine nucleoside phosphorylases
25. Phosphorolysis of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) and other 5-substituted-2′-deoxyuridines by purified human thymidine phosphorylase and intact blood platelets
26. Inhibition of uridine phosphorylase by some pyrimidine derivatives
27. Role of thymidine phosphorylase activity in the angiogenic effect of platelet-derived endothelial cell growth factor/thymidine phosphorylase
28. 7-Deazaxanthine, a novel prototype inhibitor of thymidine phosphorylase
29. Design, synthesis, and enzymatic evaluation of multisubstrate analogue inhibitors of Escherichia coli thymidine phosphorylase
30. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors
31. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides
32. Irreversible enzyme inhibitors. Thymidine phosphorylase: On the nature and dimensions of the hydrophobic bonding region
33. Pyrimidines. I. Some halogenated mono-methylpyrimidines
34. Barbituric acid
35. Substituted pyrimidines as inhibitors of yeast alcohol dehydrogenase
36. Pyrimidines. XX. A convenient preparation of orotaldehyde, and thymine-6-carboxaldehyde
37. Nucleosides. LXXVII. Synthesis of some 6-substituted uracils, and uridines by the Wittig reaction
38. Expression, characterization, and detection of human uridine phosphorylase, and identification of variant uridine phosphorolytic activity in selected human tumors
39. One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase
40. Aberrant production of gliostatin/platelet-derived endothelial cell growth factor in rheumatoid synovium
41. Autocrine induction of gliostatin/platelet-derived endothelial cell growth factor and GLS-induced expression of metalloproteinases in rheumatoid arthritis synoviocytes
42. Overexpression of the angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis
43. Evidence for participation of gliostatin/platelet-derived endothelial cell growth factor in gastric ulcer healing
44. New paradigms for the treatment of cancer: The role of anti-angiogenesis agents
45. Angiogenesis inhibition: A review
46. Clinical applications of angiogenic growth factors and their inhibitors
47. Antiangiogenic gene therapy